

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150735 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/18 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/011894

(22) International Filing Date:

11 January 2022 (11.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/135,932	11 January 2021 (11.01.2021)	US
63/155,029	01 March 2021 (01.03.2021)	US
63/160,380	12 March 2021 (12.03.2021)	US
63/192,262	24 May 2021 (24.05.2021)	US
63/227,054	29 July 2021 (29.07.2021)	US
63/277,298	09 November 2021 (09.11.2021)	US
63/284,248	30 November 2021 (30.11.2021)	US
63/296,694	05 January 2022 (05.01.2022)	US

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **FLEISHER, Adam S.**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MINTUN, Mark**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SIMS, John Randall II**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SPARKS, JonDavid**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **SHANKAR, Neelaabh et al.**; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF

(57) Abstract: The invention is directed to treatment or prevention of a disease characterized by deposition of A β in the brain using anti-N3pGlu A β antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention, in some aspects, is related to doses and dosing regimens useful for such treatments. The invention is also related to, in some aspects, human subjects who are responsive to treatment or prevention of a disease characterized by deposition of A β in the brain using anti-N3pGlu A β antibodies. The invention is also related to human subject who have one or two alleles of APOE4.



WO 2022/150735 A1